To investigate the clinical effects and safety of terbutaline combined with budesonide atomized inhalation in the treatment of children with bronchiolitis obliterans.

140 cases of children with bronchiolitis obliterans from June 2015 to June 2017 were selected as research subjects, and they were randomly divided into control group and observation group according to the digital table, with 70 cases in each group.The control group was given budesonide atomized inhalation alone, and the observation group was given terbutaline combined with budesonide atomized inhalation.The clinical effects, disappeared time of symptoms, levels of IL-4 and INF-γ before and after treatment and incidence rate of adverse effects in the two groups were compared.

The excellent effective rate and total effective rate of the control group were 28.57%, 78.57%, respectively, which were significantly lower than those of the observation group(44.29%, 95.71%) (χ²=9.73, 8.60, all P<0.05). The disappeared time of symptoms of the observation group was significantly shorter than those of the control group(t=2.67, 3.15, 2.20, 2.36, all P<0.05). The levels of IL-4 and INF-γ after treatment of the observation group were significantly higher than those of the control group and before treatment(t=2.44, 2.71, 3.07, 3.66, 2.94, 3.26, all P<0.05). The incidence rates of adverse effects of the control group and the observation group were 8.57%, 11.43%, respectively, there was no statistically significant difference between the two groups(χ²=1.49, P>0.05).

Terbutaline combined with budesonide atomized inhalation in the treatment of children with bronchiolitis obliterans can efficiently control the disease progression, shorten the clinical disease course, regulate the levels of IL-4 and IFN-γ and not aggravate the adverse drug reactions.

Bronchiolitis obliterans; Budesonide; Terbutaline; Administration, inhalation; Comparative effectiveness research; Interleukin-4; Interferon-gamma; Child